Randomized phase II trial. The study aims to investigate a different and potentially safer radio therapeutic treatment method for brain metastases. The current standard of stereotactic radiotherapy (SRT) in one or three fractions is compared to fractionated stereotactic radiotherapy (fSRT) in five fractions.
Age ≥ 18 years
At least one brain metastasis of large cell cancer suitable for SRT
Karnofsky Performance Status ≥ 70
Ability to provide written informed consent
Contra-indication for MRI scan
Primary tumor of small cell lung cancer, germinoma or lymphoma
Prior whole brain radiotherapy or SRT on the current target brain metastases (in field re-irradiation)
Presence of leptomeningeal metastases